SCHEMBL3520974

SCHEMBL3520974

CN(C)C(Cc1cccc2nc3c([nH]c4ccccc43)c(C(=O)O)c12)C(N)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 5/20 0.42
TERT O14746 4/20 0.41
TP53 P04637 1/20 0.37
CNR2 P34972 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
PBRM1 Q86U86 1/20 0.34
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.34
CDK9 P50750 3/20 0.33
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TSHR P16473 1/20 0.33
THRB P10828 1/20 0.33
HTR6 P50406 1/20 0.33
DYRK1B Q9Y463 3/20 0.33
CLK1 P49759 2/20 0.33
DYRK2 Q92630 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520770 0.82 DYRK1A (0.45) DYRK1ATERTTP53KDM4ECDK9
SCHEMBL3406646 0.76 DYRK1A (0.45) DYRK1ATERTTP53ALDH1A1KDM4E
SCHEMBL3517480 0.74 TERT (0.39) DYRK1ATERTTP53ALDH1A1KDM4E
SCHEMBL3290014 0.73 DYRK1A (0.56) DYRK1ATERTTP53PBRM1KDM4E
SCHEMBL30805770 0.73 DYRK1A (0.56) DYRK1ATERTTP53PBRM1KDM4E
SCHEMBL30805773 0.71 DYRK1A (0.54) DYRK1ATERTTP53PBRM1ALDH1A1
SCHEMBL3518356 0.71 DYRK1A (0.54) DYRK1ATERTTP53PBRM1ALDH1A1
SCHEMBL13338301 0.70 TERT (0.48) DYRK1ATERTTP53ALDH1A1KDM4E
SCHEMBL9390934 0.68 TERT (0.51) DYRK1ATERTTP53KDM4ELMNA
SCHEMBL3520973 0.68 TERT (0.47) DYRK1ATERTTP53ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331355-A1 Substituted Quinolines for the Treatment of Cancer CRYSTAX PHARMACEUTICALS, S.L. (ES) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331355-A1 Substituted Quinolines for the Treatment of Cancer TOP2B, TOP1, TOP2A DYRK1A 3740/4885TERT 1447/4885TP53 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.